European Regulators Back Amneal's Parkinson's Drug Hopledo® for Market Authorization
AMRX has more than doubled off its 52-week low of $7.665 on elevated volume (4.6× avg).
Summary
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Amneal's Hopledo® (IPX203) in Europe. This drug, already approved in the US as CREXONT®, treats Parkinson's disease with moderate to severe motor fluctuations. This is a critical step towards commercializing the drug in the significant European market, expanding Amneal's international business through its partnership with Zambon. Zambon expects a phased introduction across European markets starting October 2026, pending European Commission approval.
At the time of this announcement, AMRX was trading at $16.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $7.67 to $17.86. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.